Resistant bacterial infections

MGB Biopharma’s focus is on developing a completely new class of anti-infective medicine, starting with antibiotics which are based on Minor Groove Binder (MGBs) compounds.

The Company’s experienced management team have dedicated their initial focus to the development of a new class of small molecules, with specific antibacterial activity against susceptible and resistant bacteria. In providing a new class of drug to the field of antibacterial resistance, based on a truly novel mechanism of action, MGB Biopharma are relatively unique. A truly new class and novel MoA was last seen in the year 2000.

There are many drugs used to treat bacterial infections, and generally they belong to classes which have been in use for several decades. Due to the rise in resistant strains of bacteria, several of these drugs are becoming less and less effective.

The Company’s progress has been rapid, and its lead drug candidate, MGB-BP-3, now IND-ready and suitable for entry into Phase I clinical studies, is the first in its new exciting class of anti-infectives.

YEAR OF INVESTMENT
2010
WEBSITE
mgb-biopharma.com
OBSERVER
Sarah Hardy